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Abstract
Background and aims Atrial fibrillation (AF) is the most
frequent arrhythmia of the elderly, and electrical car-
dioversion (ECV) is a common procedure, although inci-
dence of recurrences remains high. We evaluated the
possible association between arterial stiffness (AS) and the
persistence or recurrence of AF in elderly patients after
ECV.
Methods We enrolled all subjects undergoing ECV over a
9-month period. AS was evaluated with the cardio-ankle
vascular index (CAVI). Patients were then visited at fol-
low-up (on average at 6 months).
Results Thirty-one patients (age 78 ± 7 years; men
67.7 %; CHA2DS2-VASc 4.1 ± 1.6; AF length[2 months
51.6 %; CAVI 9.9 ± 1.6) underwent ECV. At follow-up,
sinus rhythm was recorded in 16 (51.6 %) patients. At
multivariate analysis, the presence of AF was directly
associated with CHA2DS2-VASc score and CAVI. Amio-
darone therapy reduced the risk of relapsed AF.
Conclusions In elderly AF patients treated with ECV, AS
at baseline seems to predict AF at follow-up.
Keywords Arterial stiffness  Atrial fibrillation  CAVI 
CHA2DS2-VASc  Elderly  Electrical cardioversion
Introduction
Atrial fibrillation (AF) is the most common sustained
rhythm disorder of the elderly [1]. Arterial stiffness (AS)
increases with age and predicts coronary heart disease,
stroke and mortality [2]. In a previous pilot study on AF
patients, we found that AS could represent an important
factor associated with left atrium (LA) remodeling [3]. In
the present study, we evaluated whether AS has a role in
sinus rhythm maintenance in elderly subjects undergoing
elective electrical cardioversion (ECV) of persistent AF.
We also examined concentrations of interleukin-6 (IL-6),
which are associated with AS in healthy adults [4] and
early AF recurrences [5].
Methods
Patients and procedures
We enrolled all patients admitted to our day-hospital for
ECV between March and December 2015. At baseline, all
patients underwent assessment of physical and neuro-cog-
nitive function with the short physical performance battery
(SPPB) and the mini-mental state examination (MMSE).
Depressive symptoms were evaluated with the geriatric
depression scale (GDS). Venous IL-6 concentrations were
determined in 27 out of 31 (87.1 %) patients using com-
mercially available ELISA kits (R&D Systems, Inc.;
Minneapolis, MN, USA). ECV was performed using a
biphasic defibrillator, after a 4-week period of effective
oral anticoagulation [6].
The cardio-ankle vascular index (CAVI) [3, 7], a mea-
sure of AS, independent from instantaneous systolic and
pulse pressure, was evaluated immediately before
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discharge using VaSera VS-1500N (Fukuda Denshi,
Japan). During the continuous recording of EKG and heart
sounds, right and left upper and lower extremity arterial
pressure was obtained with the oscillometric method. Pulse
wave velocity (PWV) was calculated dividing the distance
from the aortic valve to the ankle by the sum of two time
intervals (1. aortic valve closing sound–notch of the bra-
chial pulse wave; 2. rise of the brachial pulse wave–rise of
the ankle pulse wave) [7]. CAVI was then computed using
the following equation:
CAVI ¼ a 2q=DPð Þ  ln Ps=Pdð Þ  PWV2
 þ b
where Ps/Pd are systolic/diastolic pressures, DP is ‘‘Ps–
Pd’’, q is blood density, and a/b are constants [7].
At follow-up, arterial blood pressure, EKG, SPPB,
MMSE, GDS and main clinical events were recorded in all
cases.
Statistical analysis
IBM SPSS forWindows (version 23) was used for statistical
analysis. Continuous and categorical variables are expressed
as mean ± SD and numbers with percentages, respectively.
Linear regression analysis described the relation between
continuous variables. Student’s t test and analysis of vari-
ance—or the related nonparametric tests—were used to
compare continuous variables between groups. The associ-
ation between categorical variables was evaluated with Chi-
square test. Logistic regression analysis models identified
clinical predictors of sinus rhythm at follow-up. A two-tailed
p value\0.05 was considered statistically significant.
Results
Study population
Thirty-eight patients underwent elective ECV. We exclu-
ded 7 subjects (18.4 % of the whole population) because of
ECV of an arrhythmia relapse (N = 3), age \55 years,
severe sinus node dysfunction, logistic reasons and refusal
to participate (N = 1 each). Characteristics of the 31
patients included in the study are reported in Table 1.
Mean age was 78 years (33rd–66th percentile:
76–80 years). On the whole, neuro-cognitive function was
preserved and prevalence of disability low.
Hypertension emerged as the most important risk factor
for AF. Arrhythmia length was[2 months in 16 subjects
(51.6 %). CHA2DS2-VASc score and AS were high. Only
7 patients (22.6 %) showed CAVI values\9 [7].
Most patients received antagonists of the renin–an-
giotensin system and beta-blockers; amiodarone was the
most frequently used antiarrhythmic drug (Table 1).
AF predictors at follow-up
ECV was effective in 90.3 % of patients (N = 28/31). At
the follow-up evaluation (mean length: 179 days, 33rd–
66th percentile: 104–252 days), sinus rhythm was observed
in 51.6 % of population (N = 16).
At follow-up, patients presenting AF tended to be older,
but no differences were observed according to gender,
neuro-cognitive and functional profile, depressive symp-
toms and history of CHF. Prevalence of diabetes, CHA2-
DS2-VASc score, baseline systolic arterial pressure, AS
and AF duration were all significantly higher in those with
AF at follow-up (Table 1; Fig. 1). Regarding drugs, only
amiodarone was associated with a higher persistence of
sinus rhythm. Subjects with AF showed higher IL-6 con-
centrations (Fig. 1); a pattern between higher levels of the
cytokine and age, diabetes, AS, CHA2DS2-VASc score,
anti-gout therapy and a poor SPPB performance also
emerged.
Multivariate logistic regression analysis demonstrated
that the presence of AF at follow-up visit was directly
correlated with the CHA2DS2-VASc score and AS, while
amiodarone therapy maintained an independent protective
association (Table 2).
Discussion
The results of the present study demonstrate that ECV is
extremely effective also in elderly patients, with a success
rate as high as 90 %. However, relapse is frequent; at
follow-up, about 50 % of our population showed AF. The
presence of the arrhythmia, due to new episodes and to
previous ECV failures, was inversely associated with
amiodarone therapy and directly related to cardio-embolic
risk and to AS, as expressed by the CHA2DS2-VASc score
and CAVI, respectively.
The efficacy of amiodarone in preventing AF recur-
rences has already been demonstrated. The ‘‘Canadian
Trial of Atrial Fibrillation Investigators’’ showed that the
incidence of arrhythmia relapses with amiodarone was
lower than that observed with sotalol or propafenone, but
the rate of adverse events was also higher [8]. More
recently, a study, conducted in the Department of Veterans
Affairs National Health Care System on subjects with a
newly diagnosed AF, found that amiodarone use was not
associated with increased mortality after adjustment for
age, gender, the presence of CHF, renal function and use of
beta-blockers and warfarin [9].
In patients undergoing electrical or pharmacological
cardioversion, the CHA2DS2-VASc score emerged as a
significant predictor of early recurrence of AF [10]. Simi-
larly, in the ‘‘Leipzig Heart Center AF Ablation Registry,’’
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Table 1 Main characteristics in
all patients and by AF at follow-
up
All patients AF at follow-up p
No Yes
Continuous variables
Age (years) 78 ± 7 74 ± 8 81 ± 4 0.005
Height (cm) 170 ± 9 170 ± 8 171 ± 9 0.593
Weight (Kg) 74 ± 14 75 ± 13 73 ± 15 0.637
MMSE (score) 27.6 ± 3.4 28.4 ± 1.5 26.9 ± 4.4 0.243
GDS (score) 3.4 ± 1.8 3.4 ± 1.6 3.4 ± 2.3 0.980
SPPB (total score) 9.6 ± 2.2 9.8 ± 2.4 9.4 ± 2.0 0.424
CHA2DS2-VASc (score) 4.1 ± 1.6 3.3 ± 1.4 5.0 ± 1.4 0.003
HR (bpm) 74 ± 14 73 ± 15 74 ± 14 0.803
SAP (mmHg) 134 ± 21 127 ± 20 141 ± 20 0.036
DAP (mmHg) 77 ± 11 75 ± 10 80 ± 11 0.178
Left atrium diameter (mm) 52 ± 4 52 ± 4 52 ± 5 0.709
IVS thickness (mm) 10 ± 1 10 ± 1 10 ± 1 0.839
LVEDD (mm) 50 ± 7 51 ± 6 49 ± 7 0.308
LVEF (%) 61 ± 9 61 ± 9 61 ± 8 0.980
Categorical variables (N, %)
Men 21 (67.7) 11 (68.8) 12 (66.7) 1.000
Living alone 6 (19.4) 2 (12.5) 4 (26.7) 0.394
Smokers (present/past) 16 (51.6) 8 (50.0) 8 (53.3) 1.000
Wine ([ 1 glass/day) 19 (61.3) 10 (62.5) 9 (60.0) 1.000
CAD 9 (29.1) 4 (25.0) 5 (33.3) 0.704
CHF 15 (48.4) 7 (43.8) 8 (53.3) 0.724
Chronic renal failure 3 (9.7) 1 (6.3) 2 (13.3) 0.600
COPD 3 (9.7) 0 (0) 3 (20.0) 0.101
CVD 4 (12.9) 2 (12.5) 2 (13.3) 1.000
Diabetes 8 (25.8) 1 (6.3) 7 (46.7) 0.015
Dyslipidemia 14 (45.2) 5 (31.3) 9 (60.0) 0.156
Hypertension 27 (87.1) 12 (75.0) 15 (100) 0.101
PAD/aortic aneurism 5 (16.2) 1 (6.3) 4 (26.7) 0.172
Thyroid dysfunction 9 (29.0) 4 (25.0) 5 (33.3) 0.704
AF length[2 months 16 (51.6) 4 (25.0) 12 (80.0) 0.004
ACE-I/ARBs 27 (87.1) 14 (87.5) 13 (86.7) 1.000
Beta-blockers 22 (71.0) 13 (81.3) 9 (60.0) 0.252
Statins 15 (48.4) 7 (43.8) 8 (53.3) 0.724
Digitalis 13 (41.9) 7 (43.8) 6 (40.0) 1.000
Amiodarone 14 (45.2) 11 (68.8) 3 (20.0) 0.011
Class IC AADs 4 (12.9 %) 1 (6.3) 3 (20.0) 0.333
OAT—warfarin 21 (67.7) 10 (62.5) 11 (73.3) 0.704
OAT—NOACs 10 (32.3) 6 (37.5) 4 (26.7)
ARBs Angiotensin receptor blockers, CAD coronary artery disease, CHF chronic heart failure, Class IC
AADs class I C antiarrhythmic drugs, COPD chronic obstructive pulmonary disease, CVD cerebrovascular
disease, GDS geriatric depression scale, HR heart rate, IVS interventricular septum, LVEDD left ventricular
end-diastolic diameter, LVEF left ventricular ejection fraction, MMSE mini-mental state examination, OAT
oral anticoagulant therapy, NOACs non-VKA oral anticoagulants, PAD/Aortic Aneurism peripheral artery
disease/aortic aneurism, SAP/DAP systolic/diastolic arterial pressure, SPPB short physical performance
battery, Wine wine consumption or equivalent for other alcoholic beverages
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the CHA2DS2-VASc score was associated with both early
and late relapses of the arrhythmia [11]. Hypertension,
diabetes and CHF, through their action on inflammation,
oxidative stress and atrial fibrosis, could represent a link
between the scores of cardio-embolic risk and AF recur-
rence [11]. Confirming this hypothesis, in our population,
we found an inverse association between IL-6 concentra-
tion and the prevalence of sinus rhythm at the follow-up.
The CHA2DS2-VASc score seems useful to identify AF
patients with a higher overall risk of events. At this regard,
in subjects with a mean age of 73.9 years, during a 2-year
follow-up, scoring 9, when compared to 0, was associated
with a three times higher risk to be admitted in hospital for
cardiovascular causes [12].
Indeed, the most interesting finding of our preliminary
experience was the direct association between AS and the
presence of arrhythmia at follow-up. For each one-unit
increase in CAVI, the risk of finding AF at the control visit
was 2.31 times higher. Few previous reports, obtained with
surrogate measures, enforced our results. After 4.9 years of
follow-up, among patients with hypertension and left
ventricular hypertrophy enrolled in the ‘‘Losartan inter-
vention for endpoint (LIFE) reduction in hypertension
study,’’ the incidence of a first episode of the arrhythmia
was 4.0 %, with a robust, significant, relation with pulse
pressure, a marker of AS [13]. Among the Framingham
Heart Study participants aged C35 years, cumulative
20-year AF incidence rates were 5.6 and 23.3 % for pulse
pressure values B40 and[61 mmHg, respectively. Hence,
AS could play a role on AF-related mechanisms also in
community-based cohorts [14].
Our results are the first to show that in an elderly pop-
ulation undergoing ECV of persistent AF, the presence of
arrhythmia at follow-up, more often a recurrence, is
directly related to arterial properties. A possible explana-
tion could be represented by the association between CAVI
and left atrium diameter, which is independent of left
ventricular thickness [3]. Once again, low-grade inflam-
mation could be the link between aortic stiffness and left
atrium dilation [15].
The small number of patients is the major limitation of
the study. IL-6 concentration was not measured in all
subjects. This fact, coupled with the collinear increase in
age, diabetes, AS and the CHA2DS2-VASc score, pre-
vented us from adjusting our models by IL-6 values.
However, this is a preliminary, pilot study. The results we
obtained are biologically and clinically plausible and could
represent the starting point for further, more detailed
investigations.
In conclusion, in an elderly AF population, the occur-
rence of arrhythmia at follow-up seems to be related not
only to CHA2DS2-VASc score and the use of amiodarone,
but also to AS. Hence, the modulation of vascular prop-
erties could represent a possible target to reduce AF burden
and its complications in aged, at-risk subjects.
Fig. 1 Arterial stiffness at baseline, measured with cardio-ankle
vascular index (CAVI), by the presence of AF at follow-up (left
panel) and proportion of patients with AF at follow-up by tertiles of
interleukin-6 (IL-6) concentration (right panel). Because right and left
CAVI values were not different (p = 0.872), we reported the left ones
for their higher statistical association with the endpoint variable
Table 2 Multivariate
predictors of the presence of AF
at follow-up visit
b ± e.s. OR (95 % CI) p
CHA2DS2-VASc (D point) 0.97 ± 0.49 2.65 (1.01–6.94) 0.048
CAVI (D unit) 0.84 ± 0.42 2.31 (1.01–5.25) 0.046
Amiodarone (yes vs. no) -2.91 ± 1.30 0.05 (0.01–0.70) 0.025
Constant -23.33 ± 10.54 / 0.027
Results of the multivariate logistic regression analysis (overall predictivity = 83.7 %)
Variables excluded from the model: baseline systolic arterial pressure (p = 0.101); AF length[2 months
(p = 0.429)
D change in the dependent variable per unitary change in the independent variable, CAVI arterial stiffness
assessed with the cardio-ankle vascular index, obtained through arterial pressure measures at the left arm
and ankle, OR odds ratio
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